HemaSphere
(Aug 2023)
P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.
- Chethan R,
- Prabath Singh Malik,
- Ranjit Kumar Sahoo,
- Raja Pramannik,
- Vikas Garg,
- Sudhir Kirar,
- Kanupriya Bhatia,
- Anura Kantak,
- Atul Sharma,
- Lalit Kumar
Affiliations
- Chethan R
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Prabath Singh Malik
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Ranjit Kumar Sahoo
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Raja Pramannik
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Vikas Garg
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Sudhir Kirar
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Kanupriya Bhatia
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Anura Kantak
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Atul Sharma
- 1 All India Institute Of Medical Sciences, New Delhi, India
- Lalit Kumar
- 1 All India Institute Of Medical Sciences, New Delhi, India
- DOI
-
https://doi.org/10.1097/01.HS9.0000969644.37507.cd
- Journal volume & issue
-
Vol. 7
p.
e37507cd
WeChat QR code